Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated Nosocomial Pneumonia

Next Previous
Trial Profile

A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated Nosocomial Pneumonia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceftolozane/tazobactam (Primary) ; Meropenem
  • Indications Nosocomial pneumonia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ASPECT-NP
  • Sponsors Cubist Pharmaceuticals

Most Recent Events

  • 04 Jul 2022 Results of retrospective subgroup analysis comparing ceftolozane/tazobactam with meropenem for treating HABP/VABP in mechanically ventilated patients, published in the Journal of Antimicrobial Chemotherapy
  • 26 Apr 2022 Results of exposure-efficacy analysis evaluating the relationship between plasma exposure of ceftolozane and tazobactam and efficacy endpoints, published in the Antimicrobial Agents and Chemotherapy
  • 12 Jan 2022 Results evaluating clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP published in the Journal of Antimicrobial Chemotherapy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top